GSK (LON:GSK) Receives Hold Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reissued by Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Monday,London Stock Exchange reports. They presently have a GBX 1,950 price objective on the stock. Deutsche Bank Aktiengesellschaft’s target price points to a potential downside of 0.26% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. Citigroup reduced their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a research note on Thursday, May 28th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, GSK currently has a consensus rating of “Hold” and an average target price of GBX 2,041.43.

GSK Stock Up 1.8%

GSK stock opened at GBX 1,955 on Monday. The firm’s fifty day moving average is GBX 1,931.52 and its 200 day moving average is GBX 1,988.92. GSK has a 12-month low of GBX 1,288.61 and a 12-month high of GBX 2,282. The company has a market capitalization of £78.31 billion, a PE ratio of 13.76, a PEG ratio of 1.24 and a beta of 0.30. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74.

GSK (LON:GSK) last issued its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. The company had revenue of GBX 762.90 billion for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. As a group, sell-side analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Vishal Sikka acquired 1,266 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, with a total value of £64,173.54. Also, insider Wendy Becker acquired 4,000 shares of the stock in a transaction dated Wednesday, April 29th. The shares were purchased at an average cost of GBX 1,963 per share, with a total value of £78,520. Over the last quarter, insiders have purchased 7,625 shares of company stock valued at $21,347,004. 0.20% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.